

# TRUSCREEN GROUP LIMITED

ARBN 644 098 760



truscreen  
a world without  
cervical cancer

The Companies Announcements Office  
The Australian Stock Exchange Limited  
SYDNEY

Date: 31 May 2021

## APPENDIX 4E

The results for announcement to the market are as follows:-

1. The reporting period is twelve months to 31 March 2021. The previous reporting period was twelve months to 31 March 2020.
2. Key information relating to the above reporting periods is as follows (Numbers are in New Zealand Dollars):-

	31 March 2021 NZ\$	31 March 2020 NZ\$	% change
Revenue from ordinary activities	1,132,641	1,288,242	(12%)
Loss from ordinary activities after tax attributable to members	(3,490,010)	(5,196,721)	33%
Net loss attributable to members	(3,490,010)	(5,196,721)	33%
Proposed dividend	-	-	-
Net tangible assets per issued security	\$0.0174	\$0.0088	120%

- 3 to 6. See attached financials.
7. No dividends have been declared or paid.
8. There is no dividend reinvestment plan in operation.
9. Net tangible assets per security are as outlined above.
10. *Acquisition or disposal of any entities occurring during the financial year.*  
Nil
11. *Any other significant information needed by an investor to make an informed assessment of the Group's financial performance and financial position.*  
Included in this document.
12. The Company is a foreign (New Zealand) company. ASX Foreign Exempt Listing. Truscreen Group Limited is incorporated in New Zealand. The financial statements have been prepared in accordance with Generally Accepted Accounting Practice ("GAAP"). They comply with New Zealand equivalents to International Reporting Standards (NZ IFRS) and International Financial Reporting Standards (IFRS), as appropriate for for-profit entities.
13. *Commentary on the results*  
See commentary and the attached financials.
14. The financial statements are subject to completion of the audit.

# TRUSCREEN GROUP LIMITED

## **Preliminary Final Report** **Consolidated Financial Statements - Unaudited**

**Currency is New Zealand Dollars**

**For the Year Ended 31 March 2021**

### **Contents**

Summary of Profit or Loss and Other Comprehensive Income	2
Statement of Financial Position	3
Statement of Changes in Equity	4
Statement of Cash Flows	5
Notes to the Financial Statements	6

**TRUSCREEN GROUP LIMITED**

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER  
COMPREHENSIVE INCOME**

**FOR THE YEAR ENDED 31 MARCH 2021**

	Note	2021	2020
		\$	\$
<b>Revenue from the sale of goods</b>	3	1,132,641	1,288,242
Other income	3	843,274	1,266,040
Changes in inventories		-	960
Purchases of inventory		(732,603)	(772,980)
Employee benefit expenses and directors' fees		(1,180,425)	(1,308,222)
Administration		(403,638)	(494,438)
Research and development expenses		(1,288,197)	(1,137,389)
Rent		(40,876)	(47,225)
Travel		(4,192)	(77,777)
Marketing & product approvals		(618,281)	(430,656)
Insurance		(85,196)	(87,410)
Shareholder relations & services		(295,163)	(148,115)
Foreign exchange gain/(loss)		(136,200)	108,038
Amortisation & depreciation		(646,598)	(597,830)
Impairment of non-current assets		-	(2,380,000)
Finance costs		(34,556)	(71,959)
Share based payments		-	(306,000)
<b>Loss before income tax</b>		<u>(3,490,010)</u>	<u>(5,196,721)</u>
Income tax expense		-	-
<b>Loss for the period</b>		<u>(3,490,010)</u>	<u>(5,196,721)</u>
<b>Other comprehensive income</b>			
<b>Item that may be reclassified subsequently to profit or loss</b>			
Exchange differences on translating foreign subsidiary operations		<u>500,136</u>	<u>(259,903)</u>
<b>Other comprehensive income /(loss) for the period</b>		<u>500,136</u>	<u>(259,903)</u>
<b>Total comprehensive loss for the period</b>		<u>(2,989,874)</u>	<u>(5,456,624)</u>
<b>Basic and diluted losses per share (cents)</b>	4	<u>(1.08)</u>	<u>(2.32)</u>

**TRUSCREEN GROUP LIMITED**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AS AT 31 MARCH 2021**

	Note	2021 \$	2020 \$
<b>CURRENT ASSETS</b>			
Cash and cash equivalents		5,255,074	1,024,153
Other receivables		558,485	684,250
Loan receivable		-	75,000
Trade receivables		-	107,018
Goods and services tax recoverable		44,233	17,510
Inventories		732,574	503,768
Other current assets – prepayments		105,931	136,442
<b>TOTAL CURRENT ASSETS</b>		<u>6,696,297</u>	<u>2,548,141</u>
<b>NON-CURRENT ASSETS</b>			
Plant and equipment		307,092	295,048
Intangible assets		5,001,302	5,230,821
<b>TOTAL NON-CURRENT ASSETS</b>		<u>5,308,394</u>	<u>5,525,869</u>
<b>TOTAL ASSETS</b>		<u>12,004,691</u>	<u>8,074,010</u>
<b>CURRENT LIABILITIES</b>			
Trade and other payables		452,594	293,141
Borrowings		-	410,280
Provision for employee benefits		205,273	83,149
<b>TOTAL CURRENT LIABILITIES</b>		<u>657,867</u>	<u>786,570</u>
<b>NON-CURRENT LIABILITIES</b>			
Provision for employee benefits		37,633	46,373
<b>TOTAL NON-CURRENT LIABILITIES</b>		<u>37,633</u>	<u>46,373</u>
<b>TOTAL LIABILITIES</b>		<u>695,600</u>	<u>832,943</u>
<b>NET ASSETS</b>		<u>11,309,191</u>	<u>7,241,067</u>
<b>EQUITY</b>			
Issued capital	5	34,550,048	27,492,050
Share option reserve	5	306,000	306,000
Foreign currency translation reserve		(214,563)	(714,699)
Accumulated losses		(23,332,294)	(19,842,284)
<b>Total Equity</b>		<u>11,309,191</u>	<u>7,241,067</u>

**TRUSCREEN GROUP LIMITED**

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 31 MARCH 2021**

Note	Share Capital \$	Accumulated Losses \$	Foreign Currency Translation Reserve \$	Option Reserve \$	Total \$
<b>Balance at 1 April 2020</b>	27,492,050	(19,842,284)	(714,699)	306,000	7,241,067
Loss for the year to 31 March 2021	-	(3,490,010)	-	-	(3,490,010)
Exchange differences on translating foreign subsidiary operations	-	-	500,136	-	500,136
<b>Total comprehensive income for the year</b>	-	(3,490,010)	500,136	-	(2,989,874)
<b>Transactions with owners, in their capacity as owners</b>					
Issue of shares	7,489,968	-	-	-	7,489,968
Share issue cost	(431,970)	-	-	-	(431,970)
<b>Total transactions with owners</b>	7,057,998	-	-	-	7,057,998
<b>Balance at 31 March 2021</b>	34,550,048	(23,332,294)	214,563	306,000	11,309,191

Note	Share Capital \$	Accumulated Losses \$	Foreign Currency Translation Reserve \$	Option Reserve \$	Total \$
<b>Balance at 1 April 2019</b>	26,421,168	(14,645,563)	(454,796)	-	11,320,809
Loss for the year to 31 March 2020	-	(5,196,721)	-	-	(5,196,721)
Exchange differences on translating foreign subsidiary operations	-	-	(259,903)	-	(259,903)
<b>Total comprehensive income for the year</b>	-	(5,046,721)	(259,903)	-	(5,456,624)
<b>Transactions with owners, in their capacity as owners</b>					
Issue of shares	1,131,800	-	-	-	1,131,800
Share issue cost	(60,918)	-	-	-	(60,918)
Employee share schemes – value of employee services	-	-	-	306,000	306,000
<b>Total transactions with owners</b>	1,070,882	-	-	306,000	1,376,882
<b>Balance at 31 March 2020</b>	27,492,050	(19,842,284)	(714,699)	306,000	7,241,067

**TRUSCREEN GROUP LIMITED**  
**CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

	Note	2021	2020
		\$	\$
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
Cash received from customers		1,167,975	1,309,080
Cash paid to suppliers and employees including GST		(4,207,886)	(4,415,470)
Cash received from research and development tax offset		689,167	1,645,985
Government subsidies		268,717	-
Short-term lease payments not included in lease liability		(73,978)	(111,002)
Interest paid		(35,146)	(71,959)
Interest received		1,820	8,867
<b>Net cash from operating activities</b>	6	<u>(2,189,331)</u>	<u>(1,634,499)</u>
<b>CASH FLOW TO INVESTING ACTIVITIES</b>			
Purchase of plant and equipment		<u>(97,524)</u>	-
<b>Net cash to investing activities</b>		<u>(97,524)</u>	-
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>			
Proceeds from issue of shares		7,489,968	1,131,800
Share issue costs		(431,970)	(60,918)
Repayment of borrowings		(410,280)	(626,501)
Proceeds from borrowings		<u>-</u>	<u>410,280</u>
<b>Net cash from financing activities</b>		<u>6,647,718</u>	<u>854,661</u>
<b>Net (decrease)/increase in cash and cash equivalents</b>		4,360,863	(779,838)
Cash and cash equivalents at the beginning of the financial year		1,024,153	1,737,775
Effects of exchange rate changes on cash and cash equivalents		<u>(129,942)</u>	<u>66,216</u>
<b>Cash and cash equivalents at the end of the financial year</b>		<u>5,255,074</u>	<u>1,024,153</u>

**TRUSCREEN GROUP LIMITED**  
**NOTED TO THE PRELIMINARY CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

**NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**General Information**

These consolidated financial statements and notes represent those of Truscreen Group Limited (formerly Truscreen Limited) and its subsidiaries (the “Group”). References to “Truscreen” is used to refer to Truscreen Group Limited (the “Company”).

The parent company, Truscreen Group Limited, is the ultimate legal parent company of the Group and is a limited liability company incorporated and domiciled in New Zealand. It is registered under the Companies Act 1993. Truscreen is listed on the NZX and on the ASX as an ASX Foreign Exempt Listing. Truscreen is a FMC reporting entity under Part 7 of the Financial Markets Conduct Act 2013.

The registered office of the Company is Level 6 Equitable House, 57 Symonds St, Grafton, Auckland 1010, New Zealand. The Group is engaged in the business of the development, manufacture and sale of cancer detection devices and systems.

**Basis of Preparation**

These financial statements have been prepared under the historical costs convention, modified by the revaluation of certain assets and liabilities as identified in specific accounting policies below.

The principal accounting policies adopted in the preparation of the financial report are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

The financial statements are presented in New Zealand Dollars. The financial statements have been rounded to the nearest dollar.

**Principles of Consolidation**

The following entities and the basis for their inclusion for consolidation in these Financial Statements are as follows:

Name of Subsidiary	Principal Place of Business	Principal Activity	Ownership Interest held by the group	
			2021	2020
Truscreen Pty Limited	Australia	Owns the rights to the Truscreen Cervical Cancer screening system. Principal operations centre	100%	100%
Truscreen Ltd (UK)	UK	Holds European Community Compliance (CE Mark). Trades to the extent necessary to satisfy requirement for VAT registration and CE Certification	100%	100%
TruScreen S. de R.L. de C.V.	Mexico	Non-operating	100%	100%

**TRUSCREEN GROUP LIMITED**  
**NOTED TO THE PRELIMINARY CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

**NOTE 2. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS**

The Company makes estimates and assumptions concerning the future that affects the amounts reported in the financial statements. Estimates and judgments are continually evaluated and based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing material adjustments to the carrying amounts of assets and liabilities within the next financial year are discussed below:

*Valuation of Intangible Assets*

Intangible assets include assets acquired at cost, net of amortisation charges, of \$3,561,162 (2020 - \$3,715,877) and costs of development of the Truscreen Gen2 device, net of amortisation charges, of \$1,440,140 (2020 - \$1,514,944). The acquired intangible assets became available for use in February 2015 when sales commenced. Amortisation of acquired intangibles commenced February 2015 and is based on a 20-year life. The development cost of TruScreen2 became available for use in April 2016. Amortisation commenced on 1 April 2016 and is based on a 20-year life. The Directors have undertaken a comprehensive Impairment Review (“Review”) of the intangible assets belonging to the Company at the reporting date. This Review has been undertaken in compliance with NZ IAS 36 (‘IAS 36’) and its detailed specifications with the assistance of an independent consultant. The impairment review is based upon projections of performance which while Truscreen is in early commercialisation phase are somewhat uncertain.

**NOTE 3. REVENUE**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Sales revenue - sale of goods		
Wholesalers/distributors	1,132,641	1,013,806
Direct to customer	-	274,436
	<u>1,132,641</u>	<u>1,288,242</u>
<b>Other income</b>		
Research and development tax offset		
- Current year	549,109 <sup>1</sup>	684,250
- Prior year adjustment	23,628	572,923
	<u>572,737</u>	<u>1,257,173</u>
Interest received	1,820	8,867
Government subsidies	268,717	-
	<u>843,274</u>	<u>1,266,040</u>

<sup>1</sup>Included in other receivables balance at reporting date.



**TRUSCREEN GROUP LIMITED**  
**NOTED TO THE PRELIMINARY CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

**NOTE 4. EARNINGS PER SHARE**

	2021	2020
<b>Basic and Diluted loss per share:</b>		
Net loss attributable to shareholders - \$	(3,490,010)	(5,196,721)
Weighted average number of ordinary shares on issue	323,761,703	224,416,746
Basic loss per share (cents) (based on weighted average number of shares on issue)	<u>(1.08)</u>	<u>(2.32)</u>

**NOTE 5. ISSUED CAPITAL**

**a) Ordinary Shares**

Group	2021 Number	2021 \$	2020 Number	2020 \$
Balance at beginning of the year of fully paid ordinary shares	227,534,804	27,492,050	216,857,441	26,421,168
Ordinary shares issued				
Share issue May 2020 @ \$0.05 per share <sup>i</sup>	104,860,021	5,242,968	-	-
Share issue December 2020 @ \$0.07 per share <sup>ii</sup>	28,571,428	2,000,000	-	-
Exercise of options <sup>iii</sup>	1,900,000	247,000	-	-
Shares issued via private placement <sup>bi</sup>	-	-	10,677,363	1,131,800
Share issue costs	-	(431,970)	-	(60,918)
Balance at 31 March	<u>362,866,253</u>	<u>34,550,048</u>	<u>227,534,804</u>	<u>27,492,050</u>

No particular number of shares are authorised. There is no par value of shares.

All issued ordinary shares carry equal rights in respect of voting and the receipt of dividends, and upon winding up rank equally with regard to the Company's residual assets.

Shares were issued during the:

a. current period:

- i. the issue of 104,860,021 new shares at \$0.05 per share raising \$5.243m. The shares were issued pursuant to a Share Purchase Plan, 40,000,000, and a share Placement Plan 64,860,021.
- ii. the issue of 28,571,428 new shares via a placement and dual listing on the ASX, raising NZ\$2.0 million at NZ\$0.07 per share (A\$0.065).
- iii. the issue of 1,900,000 new shares on exercise of options at NZ\$0.13 per share.

b. prior period:

- i. via a share placement to professional and sophisticated investors (10,677,363 ordinary shares at 10.6 cents each)

## b) Share Options

Group	2021 Number	2021 \$	Weighted Average Exercise Price	2020 Number	2020 \$	Weighted Average Exercise Price
Balance at beginning of the year	19,677,363	306,000	13.9c	-	-	-
Options issued <sup>1</sup>	-	-	-	10,677,363	-	13c
Options issued <sup>2</sup>	-	-	-	9,000,000	306,000	15c
Options exercised	(1,900,000)	-	13.0c	-	-	-
Balance at end of year	17,777,363	306,000	14.0c	19,677,363	306,000	13.9c

<sup>1</sup>Options issued on 12 July 2019 and 3 September 2019 as free attaching options on the basis of one option per new share with exercise price of 13 cents per share and expiry date 12 July 2021.

<sup>2</sup>As approved by shareholders on 27 August 2019, options issued on 25 September 2019 to Directors and senior managers with exercise price of 15 cents per share and expiry date 27 August 2022 (Note 20). The options were valued at \$306,000 using the Black & Scholes method (see Note 20).

## NOTE 6. CASH FLOW INFORMATION

	2021 \$	2020 \$
<b>Reconciliation of cash flow from operations with loss after income tax</b>		
Loss for the period	(3,490,010)	(5,196,721)
Adjusted for:		
Depreciation and amortisation	646,597	597,830
Impairment of non-current assets	-	2,380,000
Share based payment expense	-	306,000
Unrealised exchange difference arising from translating loss items at the date of transaction	298,477	(188,764)
Operating cash flows before working capital changes	(2,544,936)	(2,101,655)
Decrease in trade and other receivables	182,018	80,486
(Increase)/decrease in goods and services taxes recoverable	(26,718)	12,826
Decrease/(increase) in prepayments	30,511	(114,890)
(Increase)/decrease in inventory	(228,806)	278,258
Decrease in research and development tax offset	125,765	386,267
Increase/(decrease) in trade and other payables	241,451	(143,889)
Increase/(decrease) in employee liabilities	113,384	(31,902)
<b>Net cash applied to operating activities</b>	<b>(2,189,331)</b>	<b>(1,634,499)</b>